Danaher Corporation designs, manufactures, and markets products globally. The Biotechnology segment offers bioprocess technologies and services for therapeutic development. The Life Sciences segment provides mass spectrometers, flow cytometry instruments, and genomic medicines. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems. Danaher also provides clinical instruments, reagents, consumables, software, and services for hospitals and laboratories. The company has a research collaboration with Stanford Universitys Department of Bioengineering for cancer drug development.
| Indicator | Value |
|---|---|
| PER | 37.4 |
| EV/EBITDA | 21.8 |
| Price/Free Cash Flow' | 27.5 |
| ROIC | 10.2% |
| Net Debt/EBITDA | 1.9 |